TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Medivir AB ( (SE:MVIR) ) just unveiled an update.
Medivir AB has entered an exclusive licensing agreement with Biossil, Inc. for the global development rights of remetinostat, a clinical-stage topical HDAC inhibitor. This agreement could potentially bring Medivir up to USD 60 million and mid-single digit royalties if remetinostat is successfully developed and approved, highlighting Medivir’s commitment to innovative cancer treatments and strengthening its industry position.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir AB is a pharmaceutical company focused on developing innovative treatments for cancer, particularly in areas with high unmet medical needs. The company emphasizes collaborations and partnerships as part of its business model and is listed on Nasdaq Stockholm’s Small Cap list.
Average Trading Volume: 467,575
Technical Sentiment Signal: Sell
Current Market Cap: SEK57.98M
Find detailed analytics on MVIR stock on TipRanks’ Stock Analysis page.